Please fill out the form below and we will gladly respond as soon as possible.
New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
We are incredibly honored to share that the Synovial Sarcoma Foundation received First Place in the Advocacy in Action Award at the 16th Annual SPAGN Conference in Stockholm, Sweden. Hosted by the Sarcoma Patient Advocacy Global Network (SPAGN), this award recognizes advocacy initiatives making a meaningful impact for sarcoma patients, families, clinicians, and researchers around […]
Developing treatments for rare cancers like synovial sarcoma remains one of the biggest challenges in modern medicine—but recent progress shows what’s possible. One major milestone came with the FDA approval of Tecelra, the first engineered T-cell therapy approved for a solid tumor in the U.S., including synovial sarcoma. Why Rare Cancers Face Unique Challenges Synovial […]
Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by science, but by financial viability. As Kristen Hege, former SVP at Bristol Myers Squibb, explains:“Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s […]